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IWeS27I Relation between superantigen-induced
inflammatory cytokines severity of invasive group A
streptoeoeeal infections
Anna Norrby-Teglund
Karolinska Institute, Div. of Infectious Diseases, Huddinge, Sweden Hospital
Cytokines elicited by bacterial superantigens have been suggested to playa
central role in severe systemic clinical manifestations ofgram-positive sepsis.
Analyses of in vivo and in vitro cytokine responses in patients with severe
(streptococcal toxic shock syndrome and/or necrotizing fasciitis) or non-
severe (no toxic shock or deep-tissue involvement) group A streptococcal
invasive infection revealed a direct correlation between cytokine responses
and severity ofinvasive group A streptococcal disease. Significantly elevated
frequencies of pro-inflammatory cytokines were observed in acute phase
peripheral blood mononuclear cells from severe cases as compared to non-
severe cases. Similarly. in vivo inflammatory eytokine responses were
markedly higher in tissue biopsies of patients with necrotizing fasciitis
than in severe cellulitis/limited necrosis. Importantly. this difference in in
vivo cytokine responses during acute phase could be reproduced when paired
age and sex-matched severe and non-severe cases infected with a clonal
streptococcal strain were tested in vitro during their convalescent phase for
immune response to culture supernatants from their infecting isolate. Thus.
our data indicate that inherent host factors determine the magnitude of
cytokine responses to streptococcal superantigens. and consequently the
clinical outcome of infection. The importance of host factors, specifically
HLA class II, was further supported by in vitro experiments using cells
transfected with previously identified risk- and protective HLA class II
molecules. inasmuch as the risk HLA alleles promoted significantly stronger
responses to streptococcal superantigen than did the protective alleles.
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IWeS31 I Role of mutator alleles in the generation of multi-
resistant strains
D. Bregeon. E. Denamur, M. Fons, A. Giraud. B. Godelle. I. Matic. B.
Picard, M. Radman. F. Taddei, P. Taillez. O. Tenaillon
Genetique Moleculaire Evolutive et Medicale E9916 INSERM, Paris, France
As WHO stated in one of its report. "every bacteria possess an inherent
flexibility that enables them sooner or later to evolve antimicrobial resistance
genes". To be able to take into account some of this flexibility. we have
developed a multidisciplinary network including MDs. population geneti-
cists. ecologists and molecular biologists. Among natural isolates ofE. coli
and Salmonella the mutation rates to antibiotic resistance are higly variable
(LeClerc et al. 1996 Matic et al. 1997). Mutator alleles. such as mismatch
repair deficiency. can enhance up to lOOO-fold mutation and recombination
rate (Vulic et al. 1997).
Modelling (Taddei et al. 1997b) and experimental evolution (Chao and
Cox. 1983; Mao et al. 1997; Sniegowski et al. 1997) can show that such a high
mutation rate can be favoured and speed up bacterial adaptation to new
challenges (Taddei et al. 1997a) such as antibiotic treatment thus generating
multiresistant strains.
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The frequency ofantibiotic resistance in a bacterial population is. apart from
the volume ofantibiotic use. mainly determined by the fitness and transmis-
sion costs of resistance combined with the ability of the resistant bacteria to
compensate for these costs by mutations. Most resistances decrease bacterial
fitness as measured by competition experiments between sensitive and
resistant strains in the absence of antibiotic. These costs can be reduced by
compensatory mutations without any loss ofresistance. Recent results show
that the rate and nature of the compensatory mutations is strongly affected
by the growth environment. Thus, streptomycin- and fusidic acid resistant
Salmonella typhimurium that evolve in mice or laboratory medium obtain
different compensatory mutations. These differences in mutation spectra are
caused either by an environment-specific formation or selection of the
compcnsated mutants. These results suggest that the evolution to ameliorate
the costs ofantibiotic resistance may follow different trajectories within and
outside a bacterial host.
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IWeS36! BCG vaccination
Hans L. Rieder
International Union Agaillst Tuberculosis and Lung Disease, Paris, France
The Bacille Calmette-Guerin (BCG) vaccine. for the first time administered
by WeillHalle to a newborn child exposed to an infectious parent in July
1921 with no adverse outcome found its application rapidly spreading
within a few years. The initial indication was limited to newborn children
exposed closely to a parent with infectious tuberculosis and shown to reduce
fatality from childhood tuberculosis by some 80 per cent. Once safety ofthe
vaccine was established. the indication was expanded to children in general.
and the parenteral administration replaced the original oral vaccination
without loss ofefficacy. Today. BCG has cumulatively been given to more
children than any other vaccine. yet its value in the control of tuberculosis
remains circumspect. The vaccine has undergone several genetic mutations
and various strains of BCG exist today. and thc protection it affords varies
greatly in different situations. The IS-year follow-up results of the largest
every conducted trial. in Chingleput, South India. have just been published
and shown no protection against bacteriologically confirmed tuberculosis.
On the other extreme. BCG continues to provide. e.g.• high protection in
British school children. A variety ofhypotheses have been offered to provide
possible explanations for this variation in protective efficacy, yet none is fully
satisfactory. What is rather consistent, however, is the original notion that
BCG vaccination provides considerable protection against a fatal outcome
from serious forms of childhood tuberculosis. Its impact on the epidemio-
logical situation of tuberculosis is, on the other hand, generally accepted to
be minimal. Policy decisions on the use ofBCG must thus take into account
the frequency ofserious. not otherwise preventable forms of tuberculosis in
children versus the frequency ofadverse reactions (albeit infrequent), and the
desirability to preserve the usefulness of the tuberculin skin test in contact
investigations. as well as cost-effectiveness ofits continued use. The variation
in protective efficacy in different areas of the world would ideally require an
assessment ofits value through case-control studies in each setting faced with
a decision on the continuation or abolition of its use in routine practice,
coupled with an analysis of its cost-effectiveness.
IWeS37I Conjugate vaccines allow earlier administration of
polysaccharide vaccines
Rino Rappuoli
IRIS, Chiron SpA, Siena, Italy
Many pathogenic bacteria. including N. meningitidis, S. pneumoniae, type B
H. influenzae, produce a polysaccharide capsule that is made by many
repeating units of a simple sequence of one or more sugars. Vaccines
containing purified. high molecular weight polysaccharides induce protec-
tive immunity in adults. They were introduced in the 70s and are available
against meningococcus and pneumococcus. These vaccines induce a T-cell-
independent immunity. because polysaccharides are unable to bind the T-
cell receptor and therefore stimulate only B cells. T-cell-independent
vaccines induce an IgM-mediated antibody response that cannot be boosted
by subsequent immunizations and is effective only after two years ofage. In
infants polysaccharide vaccines usually do not work at all. To overcome the
limit of the T-cell independence of this type of vaccines. bacterial poly-
saccharides or oligosaccharides containing many repeating units have been
chemically coupled to T-cell-dependent protein antigens. The resulting
semisynthetic conjugate vaccines are T-cell-dependent and induce an 19G-
based immune response and memory. so that it can be boosted by subsequent
infection and immunization. Moreover. the conjugate vaccines have the
great advantage of working in infants below two years of age. The
development of conjugate vaccines allowed the introduction of mass
vaccination of infants against H. influenzae, that has been one of the most
successful vaccinations introduced during the last decade. In five years this
vaccination has virtually eliminated infant meningitis caused by H. inftuen-
zae in the USA and all countries where vaccination has been introduced.
Clinical trials are presently ongoing with conjugate vaccines against menin-
gococcus A and C and against the most common serotypes of pneumococ-
cus. The... vaccines will be introduced within a few ye~rs ~nd ~re expected to
eradicate most causes ofbacterial meningitis. A polysaccharide vaccine ba""d
